OUT NOW: FOXA1 mutations co-opt nascent transcription factor networks in partnership with androgen receptor to enhance prostate tumorigenicity: Cell Reports www.cell.com/cell-reports... @mskcancercenter.bsky.social @cellpress.bsky.social @erikladewig.bsky.social #SawyersLabMSKCC

Meet #MSKPostdoc Agnieszka Chryplewicz (@aga-chryplewicz.bsky.social) from the @sawyerslabmskcc.bsky.social! She studies how tumor-derived factors in prostate cancer shape immune responses to promote tumor growth and limit treatment success. #NPAW2025 🇵🇱

While our judges deliberate the top 3 winners of MSK Postdoc Slam, let’s celebrate our #NPAW2025 📸 contest champs! 🎉 🥇 @meganekelley.bsky.social – @agnelsfeir.bsky.social lab 🥈 Zhendong Cao – @sawyerslabmskcc.bsky.social 🥉 Manendra Lankadasari – Jones lab Congrats to our amazing #MSKPostdocs! 👏📷

OUT NOW: ERG-driven prostate cancer initiation is cell-context dependent and requires KMT2A and DOT1L rdcu.be/eEVKR @mskcancercenter.bsky.social @natureportfolio.nature.com #SawyersLabMSKCC

Just out: BRCA2 reversion mutation–independent resistance to PARP inhibition through impaired DNA prereplication complex function | PNAS www.pnas.org/doi/10.1073/... @mskcancercenter.bsky.social @kyriepappas.bsky.social #SawyersLabMSKCC

OUT NOW: Uncoupling of Akt and mTOR signaling drives resistance to Akt inhibition in PTEN loss prostate cancers | Science Advances www.science.org/doi/10.1126/... #SawyersLab #MSKCC @mskcancercenter.bsky.social